Cibus Gene-Editing Platforms Unvalidated at Commercial Scale, Putting Global Licensing Pipeline at Risk
San Diego-based Cibus, Inc. has not demonstrated commercial-scale proof for its RTDS and Trait Machine gene-editing platforms, which underpin its entire licensing business. Analysts rate the technological risk as catastrophic severity and medium likelihood. Seed company partners across global agricultural markets face contract exposure if field trials disappoint.
Salvado•